Stock AnalizAdaptHealth Corp. AHCO
Medical/Nursing Services · IPO 2018 · data as of November 13, 2026
AdaptHealth Corp. (AHCO) is a healthcare company listed in the US with a market value of about $1.0B. In the twelve months to September 30, 2026 it had revenue of $3.4B and net income of -$407M, a net margin of -11.8%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (1/5).
Key numbers: a price to free cash flow of 12.8, 5-year revenue growth of 25% a year, a 5-year average ROIC of -0%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 34% below the current price.
Score: 1.4 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Interest covered more than 5 times
- Share count down over 3 years (buybacks)
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.2B | $3.3B | $3.2B | $3.0B | $2.5B | $1.1B | $530M | $345M |
| Net income | -$407M | -$71M | $90M | -$679M | $69M | $156M | -$162M | -$21M | $23M |
| Free cash flow | $82M | $219M | $236M | $143M | -$18M | $72M | $156M | $39M | $58M |
| EPS (diluted) | $-2.98 | $-0.52 | $0.61 | $-5.31 | $0.33 | $0.67 | $-3.08 | $-0.95 | $1.95 |
| Net margin | -11.8% | -2.2% | 2.8% | -21.2% | 2.3% | 6.4% | -15.3% | -4.0% | 6.7% |
| ROIC | — | 2.1% | 5.0% | -15.0% | 3.2% | 4.2% | 5.9% | 6.5% | 17.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $8.86, 16% above the current price; targets range from $8.00 to $10.00; the consensus rating is “Strong buy”; expected EPS is $-0.98 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is AdaptHealth stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 34% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does AdaptHealth pay a dividend?
Not currently.
Is AdaptHealth a good stock to buy?
We do not give buy or sell advice. AdaptHealth scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.